Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’
Subcutaneous Infliximab Shows Improved Outcomes Compared To Intravenous Version
• By David Wallace
Celltrion’s subcutanous infliximab performed better than the intravenous version • Source: Shutterstock 
